Why The Tipsters Like AstraZeneca plc Better Than GlaxoSmithKline plc

AstraZeneca plc (LON: AZN) looks in better recovery shape than GlaxoSmithKline plc (LON: GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The pharmaceuticals industry is recovering pretty well from the “patent cliff” problems when a number of key drugs lost their protection in recent years, and though there’s increasing competition from generic drugs, our two big FTSE 100 players are rebuilding their pipelines strongly. The City’s tipsters seem a little tentative still, but they do seem to have a preference for AstraZeneca (LSE: AZN)(NYSE: AZN.US).

GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US) didn’t need quite the same drastic recovery strategy as AstraZeneca, and there are still a lot of analysts who don’t seem to know what to make of it. Of a sample of 28, a full 16 are on a Neutral stance, with the rest split six apiece between the Buy and Sell camps.

Short-term price targets aren’t too encouraging either, with a recent average of around 1,475p — and that’s 6% below the current price of 1,565p! There’s still an EPS fall on the cards for this year with modest growth expected in 2016, and with a forward P/E of 17 and the mooted 5.2% dividend yield only covered 1.12 times by forecast earnings, I wouldn’t be expecting much in the short term.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

More optimistic

At AstraZeneca we have 33 pundits offering their thoughts, and they’re still a bit split between 11 Buys and nine Sells, but at least that’s a bit more positive — and there’s a smaller proportion of them, at 13, sitting on the Neutral fence.

But it’s when we take a look at price targets that we see the difference. The recent average for AstraZeneca stands at 5,060p — and that’s a 13% premium on the current 4,473p price. So why the difference?

For one thing, though AstraZeneca shares are on a forward P/E of 16.3, which is above the FTSE long-term average, it’s a more modest rating that Glaxo’s — and Astra’s predicted dividend yield of 4.1% might be a little lower, but it would be 1.5 times covered by earnings.

Forecasts improving

We’ve also seen AstraZeneca forecasts improving over the past few months, with earnings for both 2015 and 2016 edging upwards. The accepted wisdom is that Astra won’t return to earnings growth before 2017, but the company keeps beating expectations and confidence in chief executive Pascal Soriot is very high — I wouldn’t be at all surprised to see 2016 turn in a small rise instead of the forecast 2% drop.

AstraZeneca is definitely looking better value to me now, and that’s even after its shares have put on 12% over the past 12 months while Glaxo’s have lost 7% — and over five years we’re looking at a 49% gain from Astra against 28% for Glaxo.

AI Revolution Awaits: Uncover Top Stock Picks for Massive Potential Gains!

Buckle up because we're about to dive headfirst into the electrifying world of AI.

Imagine this: you make a single savvy investment in some cutting-edge technology, then kick back and watch as it revolutionises entire industries and potentially even lines your pockets.

If the mere thought of riding this AI wave excites you and the prospect of massive potential returns gets your pulse racing, then you’ve got to check out this Motley Fool Share Advisor report – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And here’s the kicker – we’re giving you an exclusive peek at ONE of these top AI stock picks, absolutely free! How’s that for a bit of brilliance?

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »

Investing Articles

2 things to remember when stock markets are turbulent

US trade policy has rattled the stock markets in New York, London and elsewhere. Our writer outlines a couple of…

Read more »